Rhinitis Allergic Clinical Trial
Official title:
A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)
This is a single group, Phase IV clinical trial to assess the safety and effectiveness of Allegra® D. This study will be conducted in participants with allergic rhinitis who are 12 years of age and above. The individual study duration for each participant would be approximately 16 days (maximum of 13 days intervention + a 3-day post intervention observation). There would be 4 study visits in which the last visit can be done either telephonically or on site. Safety events would be captured for the entire study duration. In addition, the effectiveness of the study drug would be assessed using Nasal symptom score (NSS) and Total symptom score (TSS).
The individual study duration for each participant would be approximately 16 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03317015 -
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
|
Phase 3 | |
| Completed |
NCT02401191 -
A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00380705 -
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
|
Phase 4 | |
| Completed |
NCT02175485 -
Evaluation of Efficacy of Dellegra in Exposure Unit
|
Phase 4 | |
| Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 | |
| Completed |
NCT00446186 -
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
|
Phase 2 |